FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120642008> ?p ?o ?g. }

• W2120642008 endingPage "956" @default.
• W2120642008 startingPage "952" @default.
• W2120642008 abstract "BackgroundTemozolomide is an oral alkylating agent that crosses the blood–brain barrier, and has preclinical activity in breast cancer. This phase II trial sought to determine the activity and toxicity of temozolomide in metastatic breast cancer (MBC). Temozolomide was administered in a dose dense schedule of 150 mg/m2 on days 1–7 and 15–21 in a 28-day cycle.Materials and methodsPatients had unidimensional disease for response assessment by RECIST criteria, up to two prior chemotherapy regimens for MBC, and may have had brain metastases if radiation was not expected to be required within 4 weeks.ResultsNineteen women were entered on the study. All were evaluable for toxicity and 18 were evaluable for response. The median age was 54 years; 14 had prior chemotherapy for MBC and 12 had prior hormones. Sites of disease included bone, brain, liver and lung. Treatment was well tolerated with 14/19 receiving >90% planned dose intensity. Common grade 1–3 drug-related effects included nausea, fatigue, vomiting, anorexia and skin rash. Grade 3–4 hematologic toxicities included granulocytopenia and thrombocytopenia. Of the 18 evaluable patients, there were no objective responses; three had stable disease and 15 progressive disease.ConclusionsNo responses to temozolomide were documented in these heavily pretreated women with extensive MBC including brain metastases." @default.
• W2120642008 created "2016-06-24" @default.
• W2120642008 creator A5031226414 @default.
• W2120642008 creator A5033831143 @default.
• W2120642008 creator A5047113165 @default.
• W2120642008 creator A5059715152 @default.
• W2120642008 creator A5061856914 @default.
• W2120642008 creator A5077660817 @default.
• W2120642008 creator A5079076856 @default.
• W2120642008 date "2006-06-01" @default.
• W2120642008 modified "2023-10-16" @default.
• W2120642008 title "Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG)" @default.
• W2120642008 cites W1588607955 @default.
• W2120642008 cites W1917632054 @default.
• W2120642008 cites W1977392502 @default.
• W2120642008 cites W1980200619 @default.
• W2120642008 cites W1984955359 @default.
• W2120642008 cites W1985789996 @default.
• W2120642008 cites W1998299598 @default.
• W2120642008 cites W2013669698 @default.
• W2120642008 cites W2017985800 @default.
• W2120642008 cites W2096287682 @default.
• W2120642008 cites W2138045238 @default.
• W2120642008 cites W2139248078 @default.
• W2120642008 cites W2162934203 @default.
• W2120642008 cites W2167713837 @default.
• W2120642008 doi "https://doi.org/10.1093/annonc/mdl056" @default.
• W2120642008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16565212" @default.
• W2120642008 hasPublicationYear "2006" @default.
• W2120642008 type Work @default.
• W2120642008 sameAs 2120642008 @default.
• W2120642008 citedByCount "98" @default.
• W2120642008 countsByYear W21206420082012 @default.
• W2120642008 countsByYear W21206420082013 @default.
• W2120642008 countsByYear W21206420082014 @default.
• W2120642008 countsByYear W21206420082015 @default.
• W2120642008 countsByYear W21206420082016 @default.
• W2120642008 countsByYear W21206420082017 @default.
• W2120642008 countsByYear W21206420082018 @default.
• W2120642008 countsByYear W21206420082019 @default.
• W2120642008 countsByYear W21206420082020 @default.
• W2120642008 countsByYear W21206420082021 @default.
• W2120642008 countsByYear W21206420082022 @default.
• W2120642008 countsByYear W21206420082023 @default.
• W2120642008 crossrefType "journal-article" @default.
• W2120642008 hasAuthorship W2120642008A5031226414 @default.
• W2120642008 hasAuthorship W2120642008A5033831143 @default.
• W2120642008 hasAuthorship W2120642008A5047113165 @default.
• W2120642008 hasAuthorship W2120642008A5059715152 @default.
• W2120642008 hasAuthorship W2120642008A5061856914 @default.
• W2120642008 hasAuthorship W2120642008A5077660817 @default.
• W2120642008 hasAuthorship W2120642008A5079076856 @default.
• W2120642008 hasBestOaLocation W21206420081 @default.
• W2120642008 hasConcept C121608353 @default.
• W2120642008 hasConcept C126322002 @default.
• W2120642008 hasConcept C143998085 @default.
• W2120642008 hasConcept C2775930923 @default.
• W2120642008 hasConcept C2776694085 @default.
• W2120642008 hasConcept C2777389519 @default.
• W2120642008 hasConcept C2778570526 @default.
• W2120642008 hasConcept C2778822529 @default.
• W2120642008 hasConcept C2779984678 @default.
• W2120642008 hasConcept C2780580376 @default.
• W2120642008 hasConcept C2780852908 @default.
• W2120642008 hasConcept C31760486 @default.
• W2120642008 hasConcept C530470458 @default.
• W2120642008 hasConcept C71924100 @default.
• W2120642008 hasConceptScore W2120642008C121608353 @default.
• W2120642008 hasConceptScore W2120642008C126322002 @default.
• W2120642008 hasConceptScore W2120642008C143998085 @default.
• W2120642008 hasConceptScore W2120642008C2775930923 @default.
• W2120642008 hasConceptScore W2120642008C2776694085 @default.
• W2120642008 hasConceptScore W2120642008C2777389519 @default.
• W2120642008 hasConceptScore W2120642008C2778570526 @default.
• W2120642008 hasConceptScore W2120642008C2778822529 @default.
• W2120642008 hasConceptScore W2120642008C2779984678 @default.
• W2120642008 hasConceptScore W2120642008C2780580376 @default.
• W2120642008 hasConceptScore W2120642008C2780852908 @default.
• W2120642008 hasConceptScore W2120642008C31760486 @default.
• W2120642008 hasConceptScore W2120642008C530470458 @default.
• W2120642008 hasConceptScore W2120642008C71924100 @default.
• W2120642008 hasIssue "6" @default.
• W2120642008 hasLocation W21206420081 @default.
• W2120642008 hasLocation W21206420082 @default.
• W2120642008 hasOpenAccess W2120642008 @default.
• W2120642008 hasPrimaryLocation W21206420081 @default.
• W2120642008 hasRelatedWork W2015529888 @default.
• W2120642008 hasRelatedWork W2081557631 @default.
• W2120642008 hasRelatedWork W2111792237 @default.
• W2120642008 hasRelatedWork W2170352017 @default.
• W2120642008 hasRelatedWork W2243375749 @default.
• W2120642008 hasRelatedWork W2375265431 @default.
• W2120642008 hasRelatedWork W2377198612 @default.
• W2120642008 hasRelatedWork W2385117354 @default.
• W2120642008 hasRelatedWork W2411586928 @default.
• W2120642008 hasRelatedWork W2412098709 @default.
• W2120642008 hasVolume "17" @default.
• W2120642008 isParatext "false" @default.

• next